Advanced non-small cell lung cancer in elderly patients: A review

Table 5 Retrospective analyses of gefitinib in the treatment of unselected elderly patients with advanced non-small-cell lung cancer

Ref.	Previous chemotherapy	Age (yr)	No. of patients	RR (%)	SD (%)	MST (mo)	Toxicity G ≥ 3
Copin et al[58]	Yes (61%)	≥ 70	61	2 (3)	16 (26)	NR	None
	No (39%)
Cavina et al[59]	Yes (64.5%)	≥ 70	31	0 (0)	18 (58)	3.0	G3 skin 10%
	No (35.5%)						G3 diarrhoea 3%
Gridelli et al[60]	Yes (94.5%)	≥ 70	18	0 (0)	2 (11)	4.4	None
	No (5.5%)
Cappuzzo et al[61]	Yes (100%)	≥ 70	40	2 (5)	18 (45)	5.0	G4 diarrhoea 2.5%
Hotta et al[62]	Yes (57%)	≥ 75	92	16 (17)	40 (43)	7.6	G3-4 toxicity 9%
	No (43%)

RR: Response rate; SD: Stable disease; MST: Median survival time; G: Grade; NR: Not reported.